PR1 Peptide Vaccine Induces Specific Immunity With Clinical Responses In Myeloid Malignancies

PR1, an HLA-A2-restricted peptide derived from both proteinase 3 and neutrophil elastase, is recognized on myeloid leukemia cells by cytotoxic T lymphocytes (CTL) that preferentially kill leukemia and contribute to cytogenetic remission. To evaluate safety, immunogenicity and clinical activity of PR...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Leukemia
Главные авторы: Qazilbash, Muzaffar H., Wieder, Eric, Thall, Peter F., Wang, Xuemei, Rios, Rosa, Lu, Sijie, Kanodia, Shreya, Ruisaard, Kathryn E., Giralt, Sergio A., Estey, Elihu H., Cortes, Jorge, Komanduri, Krishna V., Clise-Dwyer, Karen, Alatrash, Gheath, Ma, Qing, Champlin, Richard E., Molldrem, Jeffrey J.
Формат: Artigo
Язык:Inglês
Опубликовано: 2016
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5332281/
https://ncbi.nlm.nih.gov/pubmed/27654852
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2016.254
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы